New Genetic Test Available from IIHG for Clopidogrel (Plavix®)
Tuesday, November 12, 2013
The Iowa Institute of Human Genetics (IIHG) offers pharmacogenomic testing for clopidogrel (Plavix®) response.
If you have ever taken prescription medications, you may have experienced some unintended effects – perhaps a medicine didn’t work as expected or there were harmful side effects. You are not alone. Drugs do not work in up to half of people due to their genetic make-up.
Pharmacogenomics (PGx) testing is done to determine a person’s genetic makeup affecting his or her response to a particular drug or class of drugs. This information makes precision medicine possible so that your healthcare provider can ‘personalize’ your optimal drug treatment.
Clopidogrel (Plavix®), for example, is commonly prescribed as a blood thinner to prevent heart attacks and stroke. Clopidogrel does not work properly in about 30% of patients, due to four common DNA changes in the gene CYP2C19.
The IIHG offers a simple test for these DNA variations so you can learn if clopidogrel will work for you or your patient. For more information on this test, please visit our websites for health care providers (http://www.medicine.uiowa.edu/humangenetics/cyp2c19/) and for patients (http://www.medicine.uiowa.edu/humangenetics/CYP2C19/Patients/).